BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bodei L, Kidd MS, Singh A, van der Zwan WA, Severi S, Drozdov IA, Malczewska A, Baum RP, Kwekkeboom DJ, Paganelli G, Krenning EP, Modlin IM. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging 2020;47:895-906. [PMID: 31838581 DOI: 10.1007/s00259-019-04601-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Titan AL, Norton JA, Fisher AT, Foster DS, Harris EJ, Worhunsky DJ, Worth PJ, Dua MM, Visser BC, Poultsides GA, Longaker MT, Jensen RT. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors. JAMA Netw Open 2020;3:e2024318. [PMID: 33146734 DOI: 10.1001/jamanetworkopen.2020.24318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
3 Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review. Biology (Basel) 2021;10:950. [PMID: 34681049 DOI: 10.3390/biology10100950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology 2021;298:261-74. [PMID: 33231532 DOI: 10.1148/radiol.2020201745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lassmann M, Eberlein U, Gear J, Konijnenberg M, Kunikowska J. Dosimetry for Radiopharmaceutical Therapy: The European Perspective. J Nucl Med 2021;62:73S-9S. [PMID: 34857624 DOI: 10.2967/jnumed.121.262754] [Reference Citation Analysis]
6 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Shah D, Lamarca A, Valle JW, McNamara MG. The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. J Clin Med 2021;10:403. [PMID: 33494364 DOI: 10.3390/jcm10030403] [Reference Citation Analysis]
8 Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60. [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 43.0] [Reference Citation Analysis]
9 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Reference Citation Analysis]
10 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Reference Citation Analysis]
11 Roll W, Schindler P, Masthoff M, Seifert R, Schlack K, Bögemann M, Stegger L, Weckesser M, Rahbar K. Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis. Cancers (Basel) 2021;13:3849. [PMID: 34359750 DOI: 10.3390/cancers13153849] [Reference Citation Analysis]
12 Galgano SJ, Iravani A, Bodei L, El-haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response— AJR Expert Panel Narrative Review. American Journal of Roentgenology. [DOI: 10.2214/ajr.21.27159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics (Basel) 2020;10:E1083. [PMID: 33322819 DOI: 10.3390/diagnostics10121083] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
15 Andreasi V, Partelli S, Muffatti F, Manzoni MF, Capurso G, Falconi M. Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis. 2021;53:171-182. [PMID: 32912771 DOI: 10.1016/j.dld.2020.08.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ferdinandus J, Fendler WP, Morigi JJ, Fanti S. Theranostics in oncology: What radiologists want to know. Eur J Radiol 2021;142:109875. [PMID: 34391057 DOI: 10.1016/j.ejrad.2021.109875] [Reference Citation Analysis]
18 Elf AK, Johanson V, Marin I, Bergström A, Nilsson O, Svensson J, Wängberg B, Bernhardt P, Elias E. Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. Cancers (Basel) 2021;13:2035. [PMID: 33922482 DOI: 10.3390/cancers13092035] [Reference Citation Analysis]
19 Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, Salaun PY, Kerlan V, Bourhis D, Abgral R. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study. Clin Nucl Med 2021;46:111-8. [PMID: 33234927 DOI: 10.1097/RLU.0000000000003412] [Reference Citation Analysis]
20 Paganelli G, Bodei L, Modlin I. A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm. Eur J Nucl Med Mol Imaging 2020;47:2223-6. [PMID: 32564170 DOI: 10.1007/s00259-020-04904-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, DI Iorio V, Germanò L, Caroli P, Sarnelli A, Paganelli G, Severi S. Theragnostic in neuroendocrine tumors. Q J Nucl Med Mol Imaging 2021;65:342-52. [PMID: 34881852 DOI: 10.23736/S1824-4785.21.03426-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Opalińska M, Sowa-Staszczak A, Grochowska A, Olearska H, Hubalewska-Dydejczyk A. Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors. Front Oncol 2021;11:687925. [PMID: 34868906 DOI: 10.3389/fonc.2021.687925] [Reference Citation Analysis]
23 Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022;:JCO2200176. [PMID: 35649195 DOI: 10.1200/JCO.22.00176] [Reference Citation Analysis]
24 Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:1119. [PMID: 35267427 DOI: 10.3390/cancers14051119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Colao A, de Nigris F, Modica R, Napoli C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead. Front Endocrinol (Lausanne) 2020;11:604341. [PMID: 33384663 DOI: 10.3389/fendo.2020.604341] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
27 Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L, van Leeuwen FWB, Glatting G, Lassmann M. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging 2021. [PMID: 33912987 DOI: 10.1007/s00259-021-05345-9] [Reference Citation Analysis]
28 Pirasteh A, Lovrec P, Bodei L. Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord 2021;22:539-52. [PMID: 33783695 DOI: 10.1007/s11154-021-09631-7] [Reference Citation Analysis]
29 O'neill E, Cornelissen B. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.02.004] [Reference Citation Analysis]
30 Roll W, Weckesser M, Seifert R, Bodei L, Rahbar K. Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. Eur J Nucl Med Mol Imaging 2021. [PMID: 33903926 DOI: 10.1007/s00259-021-05359-3] [Reference Citation Analysis]
31 Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, Öberg K, Modlin IM. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol 2020;21:e431-43. [PMID: 32888472 DOI: 10.1016/S1470-2045(20)30323-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
32 Chin RI, Wu FS, Menda Y, Kim H. Radiopharmaceuticals for Neuroendocrine Tumors. Semin Radiat Oncol 2021;31:60-70. [PMID: 33246637 DOI: 10.1016/j.semradonc.2020.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sundlöv A, Sjögreen-Gleisner K. Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment. Clin Oncol (R Coll Radiol) 2021;33:92-7. [PMID: 33189510 DOI: 10.1016/j.clon.2020.10.020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
35 Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S, Pappagallo G, Seregni E, Versari A. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel) 2022;14:2501. [PMID: 35626105 DOI: 10.3390/cancers14102501] [Reference Citation Analysis]